| 0.02 0.006 (42.86%) | 06-12 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term | |
|||
| Targets | 6-month : | 1-year : | ||
| Resists | First : | Second : | ||
| Pivot price | ||||
| Supports | First : | Second : | ||
| MAs | MA(5) : | MA(20) : | ||
| MA(100) : | MA(250) : | |||
| MACD | MACD : | Signal : | ||
| %K %D | K(14,3) : | D(3) : | ||
| RSI | RSI(14): | |||
| 52-week | High : | Low : | ||
| If tomorrow: | Open lower | Open higher |
| High: | - | - |
| Low: | - | - |
| Close: | - | - |
Windtree Therapeutics, Inc. is a clinical-stage biopharmaceutical firm primarily dedicated to developing therapies for acute cardiovascular ailments, and secondarily for acute pulmonary diseases. Its prominent therapeutic programs include istaroxime, undergoing Phase IIb clinical trials for acute decompensated heart failure and Phase IIa for early cardiogenic shock; AEROSURF, an aerosolized KL4 surfactant in Phase IIb for respiratory distress syndrome in preterm infants; Lyophilized KL4 surfactant, in Phase IIa trials for lung injury stemming from COVID-19; and Rostafuroxin, in Phase IIb for genetically associated hypertension. The company maintains collaborations, including one with Universita degli Studi di Milano-Bicocca for the discovery and advancement of novel SERCA2a compounds targeting chronic and acute human heart failure. It also holds a strategic alliance with Laboratorios del Dr. Esteve, S.A. for the development, marketing, and commercialization of a portfolio of potential KL4 surfactant products, and a collaboration with Battelle Memorial Institute to further develop its ADS for its Phase III program. Established in 1992 as Discovery Laboratories, Inc., the company rebranded as Windtree Therapeutics, Inc. in April 2016. It is headquartered in Warrington, Pennsylvania, and operates as a subsidiary of Lee's Pharmaceutical Holdings Limited.
Wed, 22 Apr 2026
WINT Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Tue, 17 Mar 2026
AI mortgage marketplace CommLoan goes nationwide, pursues reverse merger - Stock Titan
Tue, 23 Dec 2025
Windtree Therapeutics Announces the Sale of its Cardiovascular Biotech Pipeline Drug Candidates - GlobeNewswire
Mon, 06 Oct 2025
Windtree Therapeutics settles real estate dispute, receives $750,000 from escrow - Investing.com
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Outperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
OTC
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 0 (M) |
| Shares Float | 0 (M) |
| Held by Insiders | (%) |
| Held by Institutions | (%) |
| Shares Short | 0 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | |
| EPS Est Next Qtrly | |
| EPS Est This Year | |
| EPS Est Next Year | |
| Book Value (p.s.) | |
| Profit Margin | % |
| Operating Margin | % |
| Return on Assets (ttm) | % |
| Return on Equity (ttm) | % |
| Qtrly Rev. Growth | % |
| Gross Profit (p.s.) | |
| Sales Per Share | |
| EBITDA (p.s.) | |
| Qtrly Earnings Growth | % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | 0 (M) |
| PE Ratio | |
| PEG Ratio | |
| Price to Book value | |
| Price to Sales | |
| Price to Cash Flow |
| Dividend | |
| Forward Dividend | |
| Dividend Yield | 0% |
| Dividend Pay Date | |
| Ex-Dividend Date |
|
|
|
|
|
|
|
|
|